Figure 2.

Targeted AcTaferon delivery to B16 tumors controls tumor growth without toxicity. (A) Growth of s.c. inoculated B16-mCD20⁺ tumors in syngeneic C57BL/6J mice after treatments with PBS, mCD20-mIFN (immunocytokine) or hCD20-mIFN (untargeted mIFN), mCD20-AFN (targeted) or hCD20-AFN (untargeted), or mCD20-hIFN as a negative control for “sdAb-only” effects. Shown is a representative experiment of 7 independent repeats (n = 5 mice per group), arrows indicate treatment days. (B) Seven independent experiments were pooled to plot the time necessary for each mouse to reach a tumor of 70 mm² (total n = indicated in the legend). (C) Body weight changes of tumor-bearing mice treated with mCD20-targeted mIFN or AFN (n = 5). (D-I) Hematological analyses (platelet counts, mean platelet volume, red blood cell, neutrophil, monocyte and lymphocyte counts) in fresh EDTA-blood collected 1 day after the last treatment. ‘Naive mice’ are tumor-free, ‘tumor mice’ are tumor-bearing treated with PBS. All values depicted are mean ± s.e.m.; *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001 compared with PBS treated animals unless otherwise indicated; by two-way ANOVA with Dunnett's multiple comparison test (A, C), one-way ANOVA with Dunnett's multiple comparison test (D-I) or log-rank test (B). Shown are representative results of 7 independent repeats (C-I).